The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Panel Backs Amgen Biosimilar of Humira

FDA Panel Backs Amgen Biosimilar of Humira

July 13, 2016 • By Toni Clarke

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—Amgen Inc.’s cheaper version of AbbVie’s top-selling arthritis drug adalimumab (Humira) is highly similar to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.

You Might Also Like
  • FDA Panel Supports Novartis Biosimilar of Etanercept
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira

The panel voted 26–0 that the drug, ABP 501, which was studied in rheumatoid arthritis and plaque psoriasis, was similar in safety and effectiveness to the original.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

AbbVie is trying to block Amgen’s drug from reaching the market. It claims it has patents in place to protect Humira, the world’s biggest-selling drug, in the U.S. until at least 2022.

The panel concluded that the study results could be extrapolated to other conditions for which Humira is approved, including adult Crohn’s disease and ulcerative colitis and should be approved for those conditions as well.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA is not obliged to follow the advice of its advisory committee, but typically does so. The panel’s conclusions were consistent with those of FDA scientists, who published their preliminary review of the drug on Friday.

Panelists had some reservations about approving the drug for indications for which it had not been tested in clinical trials and urged the FDA to require companies to conduct post-market surveillance studies to make sure the product works as expected in those conditions.

“I voted yes despite reservations about extrapolating from the data we have, which was good, to the data we don’t have and will never have,” says Nancy Geller, a biostatistician at the National Institutes of Health.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Panelists also urged greater education of the public about biosimilars, copies of biologic drugs made from living cells. Biosimilars are more complex than traditional pills and cannot be copied with precision. Biosimilars are not interchangeable with the original product.

Amgen could introduce its drug before the patent dispute with AbbVie is resolved, but risks facing triple damages from an unfavorable court ruling. Some analysts expect the drug to be available well before 2022 and expect sales of Humira to fall as much as 18% in 2019.

Humira last year generated U.S. sales of more than $8 billion.

On Wednesday the panel will vote on whether the FDA should approve Novartis AG’s cheaper version of Amgen’s arthritis drug Enbrel. Enbrel and Humira both block tumor necrosis factor.

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: ABP 501, adalimumab, FDA, Food and Drug Administration, plaque psoriasis, Rheumatoid Arthritis (RA)

You Might Also Like:
  • FDA Panel Supports Novartis Biosimilar of Etanercept
  • FDA Approves Adalimumab-atto, a Biosimilar of Humira
  • FDA Staff Says Amgen Biosimilar ‘Highly Similar’ to AbbVie’s Humira
  • FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)